Gyre Therapeutics, Inc. (GYRE) — 10-Q Filings
All 10-Q filings from Gyre Therapeutics, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Gyre Therapeutics' Q3 Net Income Soars, Cash Reserves Bolstered
— Nov 7, 2025 Risk: medium
GYRE THERAPEUTICS, INC. reported a net income of $5.9 million for the three months ended September 30, 2025, a significant increase from $2.9 million in the sam -
GYRE's Losses Widen Amid R&D Push, No Revenue Reported
— Aug 11, 2025 Risk: high
GYRE THERAPEUTICS, INC. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods, indicating its pre-commerc -
Gyre Therapeutics Files Q1 2025 10-Q
— May 9, 2025 Risk: medium
Gyre Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Catalyst BioSciences, Inc., reported financial resul -
Gyre Therapeutics Files Q3 2024 10-Q
— Nov 13, 2024 Risk: medium
Gyre Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial performance and business operations, incl -
Gyre Therapeutics Files Q2 2024 10-Q
— Aug 13, 2024 Risk: medium
Gyre Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results and provided updates on its business operatio -
Gyre Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024
— May 13, 2024 Risk: medium
GYRE THERAPEUTICS, INC. (GYRE) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Gyre Therapeutics, Inc. (GYRE) filed a 10-Q report for the period e
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX